The placement device for the LivIQ leadless pacemaker. [Image courtesy of Biotronik] Biotronik today announced the initiation ...

International BIO-LivIQ Study Will Generate Evidence for Global LivIQ Leadless Pacemaker Approvals; Far-Field Sensing and ...

The prospective multi-centre BIO-LivIQ trial will enrol 325 patients across 60 sites worldwide.

NEW ORLEANS, May 20, 2023 /PRNewswire/ -- Abbott today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to ...

Add Yahoo as a preferred source to see more of our stories on Google. A Bakersfield hospital Monday became the first in Kern County to successfully implant the AVEIR DR, the world's first dual-chamber ...

Abbott ABT recently received FDA approval for its pioneering AVEIR dual chamber (DR) leadless pacemaker system. The approval comes following the recent late-breaking clinical trial data showing that ...

Commencement of LEADLESS II clinical research trial represents important milestone in bringing transformational pacing technology to U.S. patients ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, ...

JANESVILLE, Wis. -- Two Mercyhealth hospitals performed its first dual leadless pacemaker procedures. Mercyhealth Hospital and Trauma Center-Janesville and Javon Bea Hospital-Riverside have each ...

Though the FDA approval for Abbott’s first leadless pacemaker comes several years after its competitor Medtronic achieved the feat, the devicemaker is aiming to up the tempo. Like its peers in the ...

Patients who require a new permanent pacemaker after TAVI do just as well with leadless devices out to 2 years as they do with transvenous pacemakers, according to an analysis of real-world data from ...

Please provide your email address to receive an email when new articles are posted on . Abbott announced that the FDA has approved its Aveir VR single-chamber leadless pacemaker for the treatment of ...

A leadless right-ventricular pacemaker continued to show an edge over conventional transvenous pacemakers by triggering a substantially reduced rate of complications during the 6 months following ...